This content is from: Research

Health Care: Biotechnology 2008

Mark Schoenebaum, who joined Deutsche Bank Securities in June, after his former firm, Bear, Stearns & Co., was absorbed by ­JPMorgan Securities, remains “one of the most accessible, friend­ly and knowledgeable analysts in the sector,” according to one hedge fund man­ager.

Mark Schoenebaum

Mark Schoenebaum

Deutsche

SECOND TEAM

Geoffrey Meacham ­JPMorgan

THIRD TEAM

Geoffrey Porges Sanford C. Bernstein

Mark Schoenebaum, who joined Deutsche Bank Securities in June, after his former firm, Bear, Stearns & Co., was absorbed by ­JPMorgan Securities, remains “one of the most accessible, friend­ly and knowledgeable analysts in the sector,” according to one hedge fund man­ager. Schoenebaum, 35, also remains No. 1 for a fourth consecutive year. He initiated coverage of Genen­tech in June with a buy rating, at $74.36, on the belief that Swiss drug­maker Roche Holding, which owns a controlling interest in the San ­Francisco–based cancer treatment developer, would be unsuccessful in its attempts to acquire the remaining shares. He was right. By mid-­September, Genentech’s stock had shot up to $96.56 — a healthy 29.9 percent gain that outperformed the sector by 15.3 percentage points. Geoffrey ­Meacham of ­JPMorgan Securities leaps from ­runner-up to second place, thanks in part to what clients call “a great sense for how much a potential drug is really worth” and “fast, insightful reactions.” In December, Meacham high­lighted his long-­standing buy recommendation on Celgene Corp., reasoning that rising demand in Europe for the Summit, New ­Jersey–based com­pany’s myeloma treatment drug Rev­limid would more than offset competitive threats in the U.S. By mid-­September the stock had ­soared 44.7 percent. Although he slips one notch to third, Geoffrey Porges of Sanford C. Bernstein & Co. continues to impress investors with what one ­backer calls “in-depth, exquisitely thoughtful work.” In May, Porges upgraded Cambridge, ­Massachusetts–based Genzyme Corp. to buy, at $68.01, on its growing pipeline. By mid-­September the stock had risen 17.4 percent, to $79.85.

Return to The Best Analysts of the Year

Return to Rankings

Related Content